Testing the safety of aPCC after emicizumab in hemophilia A
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe hemophilia A, with very low factor VIII (below 0.05 IU/mL) before you developed an inhibitor
- You are at least 6 years old when you sign consent
- You have a high-titer inhibitor confirmed on two blood tests, with a 72-hour washout, within 2 years of joining
- Your blood counts are high enough (hemoglobin above 8 g/dL and platelets above 100,000 per microliter)
- Your liver and kidney tests are within allowed ranges for the study
- You are able to follow the study plan and consent is provided by you or your legal guardian
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.